Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-02-23

Clinical Trial Update: Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating liposomal annamycin for acute myeloid leukemia has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Liposomal Annamycin (annamycin liposome)

Snippet

Sponsor: Moleculin Biotech, Inc. | Conditions: Leukemia, Myeloid, Acute | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-02-23